Docetaxel KOL Commentaries - Docetaxel KOL Commentary Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicitiesMary-Ellen Taplin VIEW MORE Case study Case Study (2019-2023): Changing treatmentsMary-Ellen Taplin VIEW MORE Case study mHSPC: A Clinical Case StudyJordan Ciuro & Atish Choudhury VIEW MORE KOL Commentary Updates in mHSPC ASCO Genitourinary Symposium 2023Atish Choudhury & Jordan Ciuro VIEW MORE Case study Patient Case StudyWilliam Oh VIEW MORE Infographics - Docetaxel Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer VIEW INFOGRAPHIC Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer VIEW INFOGRAPHIC Intensifying Metastatic Hormone-Sensitive Prostate Cancer Treatment VIEW INFOGRAPHIC Articles - Docetaxel Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy READ MORE Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer READ MORE Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis READ MORE Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer READ MORE Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial READ MORE Facebook Twitter Linkedin
